Short-Term Debt to Equity Ratio: Athira Pharma, Inc. (ATHA)
Historical price action reflects the financial standing of Athira Pharma, Inc. (ATHA), whose strategy is based on developing drugs for the regeneration of neural connections in Alzheimer's disease. Athira Pharma, Inc. (ATHA) utilizes unique cell growth stimulation methods to combat brain degradation. The current metric is 0.01. The stability of scientific research is maintained through the seamless operation of modern laboratory complexes and screening systems.
Analytical breakdowns for Athira Pharma, Inc.
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Athira Pharma, Inc.|ATHA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Athira Pharma|ATHA - Company Cumulative Indebtedness|Debts to Book Capitalization Athira Pharma Inc|ATHA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Athira Pharma|Quick Liquidity athira.com
- company profitability and valuation multiples indicators:
Summary company analysis:Athira
This ratio determines the company's dependence on liabilities maturing within one year relative to its equity, serving as an indicator of financial autonomy and protection against sudden defaults. By analyzing the short-term debt-to-equity chart, an investor will see the critical dependence of Athira Pharma, Inc. (ATHA) on liquidity, as the lack of profit makes any borrowing a fatal risk to the project's survival.
Direct competitors
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Capital denalitherapeutics.com|Short-Term Debt to Equity Ratio HRMY (Harmony Biosciences Holdings, Inc.)|Short-Term Loans to Capital Ratio BHVN|Short-Term Debt to Capital AMLX (Amylyx)|Ratio of Short-Term Indebtedness to Capital TRVI|Praxis Precision Medicines - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient anavex.com AVXL|CeriBell (CBLL) - Short-Term Debt to Equity|Prothena Biosciences - Ratio of Short-Term Indebtedness to Capital|ALEC (Alector Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital Annexon Biosciences Inc.|Short-Term Debt to Equity Ratio OMER (Omeros Corporation)|NGNE (neurogene.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity AC Immune SA ACIU|VYGR (Voyager Therapeutics Inc) - Current Liabilities to Equity|Neumora Therapeutics Inc - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital SCLX (Scilex Holding Company, Inc.)|TVGN: Short-Term Debt to Capital|Alpha Cognition Inc. (ACOG) - Short-Term Debt to Capital|Short-Term Debt to Equity Cognition Therapeutics, Inc.|IKT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Cassava (SAVA)|Short-Term Debt to Equity Ratio assertiotx.com ASRT|Short-Term Debt to Capital COYA (Coya Therapeutics)|Short-Term Debt to Capital VistaGen Therapeutics, Inc. VTGN|OVID: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital ABOS (Acumen Pharmaceuticals Inc.)|CRVO: Short-Term Debt to Capital|ATHE - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Clene Inc|Short-Term Debt to Capital Ratio PEPG (PepGen Corp)|Short-Term Debt to Capital JUNS|Short-Term Debt to Equity Ratio Relmada Therapeutics Inc RLMD|Annovis Bio Corp - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Coefficient Grace Therapeutics Inc (GRCE)|Firefly Neuroscience, Inc - Short-Term Debt to Capital|KLTO - Short-Term Debt to Capital|NRSN (neurosense-tx.com) - Short-Term Debt to Equity Ratio|RVPH: Short-Term Loans to Capital Ratio|MTVA (MetaVia Inc.) - Short-Term Debt to Capital|NRXS: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital HSDT|Short-Term Debt to Capital passagebio.com (PASG)|Short-Term Debt to Equity Neuphoria Therapeutics NEUP|NERV: Short-Term Debt to Capital Ratio|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|Current Liabilities to Capital Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Short-Term Debt to Equity Ratio|Protagenic Therapeutics, Inc. (PTIX) - Short-Term Debt to Capital|Short-Term Debt to Equity Pasithea Therapeutics Corp|CRGT: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BCLI - Current Liabilities to Capital|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|Short-Term Debt to Capital chromocell.com CHRO|ELYM: Short-Term Debt to Equity Ratio|Intra-Cellular Therapies - Short-Term Loans to Capital Ratio|LBPH: Short-Term Debt to Capital|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|NKGN (NKGen Biotech, Inc.) - Short-Term Debt to Capital|neurobopharma.com (NRBO) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX (Synaptogenix Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital TRVN (Trevena, Inc)|Short-Term Debt to Capital Vigil Neuroscience Inc. VIGL|WENA: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital CERE (cerevel.com)